This comprehensive case study explores Kymanox’s approach to identifying qualified Contract Manufacturing Organizations (CMOs) and developing detailed product and process documentation through innovative evaluation and communication strategies. Our team of SMEs collaborated closely with stakeholders to implement measurable improvements across CMO selection, process clarity, and regulatory alignment to enable seamless third-party selection and manufacturing readiness.
CHALLENGE
SOLUTION
RESULTS
- Identify and evaluate CMOs for Drug Product (DP) and Active Pharmaceutical Ingredient (API) manufacturing with strong regulatory and quality alignment.
- Develop Detailed Product and Process Descriptions (DPPDs) to support seamless future technology transfer and regulatory submissions.
- Conducted extensive due diligence, assessing over 50 CMOs for DP and ten (10) for API. Potential suppliers were compared using tailored scorecards and matrix comparisons to evaluate capabilities, quality systems, and regulatory compliance history.
- Facilitated transparent communication between Client and CMOs, presenting findings to executive leadership and guiding successful CMO selection and technology transfer initiation.
- Developed robust, comprehensive DPPDs by reviewing New Drug Application (NDA) and validation documents. From there, Kymanox SMEs assessed Critical Quality Attributes (CQAs), process parameters, and analytical methods to create a definitive manufacturing reference.
- Secured qualified CMO partners aligned with both quality and regulatory expectations.
- Delivered detailed DPPDs that ensured process clarity, traceability, and regulatory compliance throughout manufacturing.
- Strengthened Kymanox’s position as a trusted partner in project management and technical leadership for DP and API manufacturing operations.